Figure 5.
Figure 5. Relationship between decrease in CCL18 plasma levels and lumbar spine bone marrow fat fraction. (A-C) Inverse relationship between the decrease in plasma CCL18 levels and increase in lumbar spine marrow fat fraction on enzyme replacement therapy. Patient A: Spearman ρ –0.952; P = .0011; patient B: Spearman ρ –0.802; P = .0218; patient C: Spearman ρ –0.815; P = .0108 (•, CCL18; □, bone marrow fat fraction). Right hand side shows changes in the bone marrow fat fraction of the lumbar spine during enzyme replacement therapy as visualized by QCSI.

Relationship between decrease in CCL18 plasma levels and lumbar spine bone marrow fat fraction. (A-C) Inverse relationship between the decrease in plasma CCL18 levels and increase in lumbar spine marrow fat fraction on enzyme replacement therapy. Patient A: Spearman ρ –0.952; P = .0011; patient B: Spearman ρ –0.802; P = .0218; patient C: Spearman ρ –0.815; P = .0108 (•, CCL18; □, bone marrow fat fraction). Right hand side shows changes in the bone marrow fat fraction of the lumbar spine during enzyme replacement therapy as visualized by QCSI.

Close Modal

or Create an Account

Close Modal
Close Modal